Testing for chlamydia
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Chlamydia testing is accurate and simple, and the usual way it goes wrong is not the test. It is testing the wrong site.
Up to 70 to 90 percent of infections cause no symptoms at all, so for most people this is found by screening rather than by investigating a complaint.
Related pages: Chlamydia
The bottom line
- Nucleic acid amplification testing is the standard and is highly accurate.
- Urine testing alone misses rectal and throat infection.
- Self-collected swabs perform as well as clinician-collected ones.
- Annual screening is recommended for sexually active women under 25.
- How much undetected pharyngeal infection contributes to onward transmission.
- Whether screening men would reduce infection in their partners, which trials have not settled.
The story, step by step
- 1. The test ()
- 2. Which sites ()
- 3. Timing ()
- 4. Screening ()
What the evidence labels mean
What a NAAT is, and what it needs
What happens
The sample matters more than the technique.
What the research shows
- Nucleic acid amplification testing detects chlamydia's genetic material and is far more sensitive than the older culture and antigen methods.
- For women, a vaginal swab is the preferred sample. For men, first-catch urine, meaning the first 20 to 30 millilitres of the stream, ideally at least an hour after last urinating.
- Self-collected vaginal, rectal and throat swabs perform as well as clinician-collected ones. If an examination is the reason you are putting off testing, this is worth knowing.
- Cervical swabs taken during a pelvic examination are equally accurate but no more so, which is why a vaginal swab is usually offered instead.
- Home testing kits that post a sample to a laboratory use the same NAAT technology. A positive result still needs clinical follow-up for treatment and partner notification.
Why it matters
There is rarely a good reason to have a more invasive sample taken than you are comfortable with, because the simpler ones are just as good.
What's still uncertain
- The best sampling approach for throat infection, where sensitivity is lower than at other sites.
Read more
- CDC: STI screening recommendationsGovernment
- CDC: ChlamydiaGovernment
- MedlinePlus: Chlamydia infectionsGovernment
Next: Which sites
Why urine alone is not enough
What happens
The most common reason an infection is missed.
What the research shows
- Chlamydia infects the urethra, cervix, rectum and throat. A urine test or vaginal swab tells you nothing about the rectum or the throat.
- Rectal chlamydia is common and is often present without any history of anal sex, probably through local spread. It is also the site where the choice of antibiotic matters most.
- Pharyngeal infection is usually symptom-free and acts as a reservoir.
- Site-specific swabs should be collected based on the kinds of sex you have had, which means the clinician has to ask and you have to answer specifically. A general reassurance that everything is covered usually means urine only.
- If you have a negative result and ongoing symptoms, ask which sites were actually tested.
Why it matters
This is the single most actionable thing on the page. Three-site testing finds infections that urine testing is structurally incapable of finding.
What's still uncertain
- How much extragenital screening reduces population-level transmission, which modelling suggests is substantial and trials have not measured.
Read more
- CDC: STI screening recommendationsGovernment
- CDC: ChlamydiaGovernment
- CDC: STI treatment guidelines, chlamydial infectionsGovernment
Next: Timing
How soon after exposure
What happens
When a result can be trusted.
What the research shows
- NAATs can detect chlamydia within about 1 to 2 weeks of exposure, and some infections are detectable sooner.
- A test taken within a few days of exposure may be negative even though infection is present. If that is your situation, test now and again at around two weeks.
- If a partner has been diagnosed, treatment is usually given without waiting for your own test, because the chance of infection is high and the treatment is short.
- Do not retest immediately after treatment. A NAAT can stay positive for several weeks after the bacteria are dead, which is why any test of cure is delayed about 4 weeks.
- Retest at 3 months after treatment for reinfection, which is a separate question from whether the treatment worked.
Why it matters
Testing too early and testing too soon after treatment are the two timing errors that produce misleading results in opposite directions.
What's still uncertain
- The exact earliest reliable detection time, which varies by site and by individual.
Read more
- CDC: STI treatment guidelines, chlamydial infectionsGovernment
- CDC: STI screening recommendationsGovernment
- CDC: ChlamydiaGovernment
Next: Screening
Who, and how often
What happens
Finding it before it causes damage.
What the research shows
- Annual screening is recommended for all sexually active women under 25, and for older women with risk factors such as a new partner or multiple partners.
- Gay and bisexual men and other men who have sex with men, people taking HIV PrEP, and people living with HIV should have multi-site screening every 3 to 6 months.
- Everyone should be screened at the first prenatal visit, with retesting in the third trimester for those at continuing risk.
- Routine screening of heterosexual men is not currently recommended in most settings, mainly because of cost-effectiveness rather than because infection is rare in them. That is a live argument, since untreated men are a major source of reinfection in women.
- Screening is offered without symptoms by design. Waiting for symptoms means waiting for something that in most infections never arrives.
- Anyone diagnosed with one STI should be tested for the others, including HIV and syphilis.
Why it matters
Screening exists to prevent pelvic inflammatory disease and tubal damage, which develop silently in a proportion of untreated infections.
What's still uncertain
- Whether screening programmes have reduced pelvic inflammatory disease at population level, where the evidence is mixed and debated.
Read more
- USPSTF: Screening for chlamydia and gonorrheaGovernment
- CDC: STI screening recommendationsGovernment
- CDC: ChlamydiaGovernment